A new Journal of Clinical Psychiatry study from the Mayo Clinic found that ketamine and esketamine treatment can significantly reduce emergency department visits related to suicidality in patients with treatment-resistant depression. Researchers reviewed records of 97 patients and compared the six months before treatment with the six months after. They found an 84% drop in visits for suicidal thoughts and a 63% drop in overall suicidality-related visits. The findings suggest that ketamine offers not only rapid relief for depressive symptoms but also a sustained reduction in crisis-driven hospital use.